FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies

Oncotarget

Volumn 4, Issue 5, 2013, Pages 729-738

  Cipriano, Rocky ^a   Miskimen, Kristy L S ^a   Bryson, Benjamin L ^a   Foy, Chase R ^a   Bartel, Courtney A ^a   Jackson, Mark W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CRAF; Drug resistance; FAM83B; PI3K; Transformation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA SUBUNIT; PHOSPHATIDYLINOSITOL 3 KINASE P85ALPHA SUBUNIT; PROTEIN FAM83B; PROTEIN KINASE B; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FAM83B GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE; PRECIPITATION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TUMOR GROWTH;

EID: 84880252124     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1027     Document Type: Article

References (21)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000.100(1):57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011. 144(5):646-74.
3. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, Tzivion G. Raf kinases: function, regulation and role in human cancer. Biochim.Biophys.Acta. 2007. 1773(8):1196-212.
4. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008. 27(41):5497-510.
5. Adams JR, Schachter NF, Liu JC, Zacksenhaus E, Egan SE. Elevated PI3K signaling drives multiple breast cancer subtypes. Oncotarget. 2011. 2(6):435-47.
6. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol.Med. 2007. 13(10):433-42.
7. Grant S. Cotargeting survival signaling pathways in cancer. J.Clin.Invest. 2008. 118(9):3003-6.
8. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene. 2007. 26(22):3291-310.
9. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011 2(3):135-64.
10. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/ Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012. 3(10):1068-111.
11. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012. 3(9):954- 87.
12. McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, et al. Advances in targeting signal transduction pathways. Oncotarget. 2012. 3(12):1505-21.
13. Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, Brown HA, Stark GR, Jackson MW. FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J.Clin.Invest. 2012. 122(9):3197-210.
14. Lee SY, Meier R, Furuta S, Lenburg ME, Kenny PA, Xu R, Bissell MJ. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J.Clin.Invest. 2012. 122(9):3211-20.
15. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget. 2010. 1(7):497-514.
16. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Arteaga CL, Lindsley CW, Brown HA. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat. Chem.Biol. 2009. 5(2):108-17.
17. Kan CE, Patton JT, Stark GR, Jackson MW. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. Cancer Res. 2007. 67(20):9862-8.
18. Cipriano R, Patton JT, Mayo LD, Jackson MW. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis. Cell Cycle. 2010. 9(7):1373-9.
19. Cipriano R, Kan CE, Graham J, Danielpour D, Stampfer M, Jackson MW. TGF-beta signaling engages an ATM-CHK2- p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc.Natl.Acad.Sci.U.S.A 2011. 108(21):8668-73.
20. Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD. Hdm2 nuclear export, regulated by insulinlike growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J.Biol.Chem. 2006. 281(24):16814-20.
21. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006. 66(6):3169-76.